Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Depreciation & Amortization (CF) (2023 - 2025)

Compass Therapeutics' Depreciation & Amortization (CF) history spans 3 years, with the latest figure at $17000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 87.86% year-over-year to $17000.0; the TTM value through Dec 2025 reached $276000.0, down 53.14%, while the annual FY2025 figure was $276000.0, 53.14% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $17000.0 at Compass Therapeutics, down from $19000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $194000.0 in Q1 2023 and bottomed at $17000.0 in Q4 2025.
  • The 3-year median for Depreciation & Amortization (CF) is $147500.0 (2024), against an average of $130333.3.
  • The largest YoY upside for Depreciation & Amortization (CF) was 9.09% in 2025 against a maximum downside of 87.86% in 2025.
  • A 3-year view of Depreciation & Amortization (CF) shows it stood at $161000.0 in 2023, then fell by 13.04% to $140000.0 in 2024, then crashed by 87.86% to $17000.0 in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Depreciation & Amortization (CF) are $17000.0 (Q4 2025), $19000.0 (Q3 2025), and $100000.0 (Q2 2025).